Form 4: Monopar COO's Equity Vesting & Tax Withholding

Monopar Therapeutics' COO, Andrew Cittadine, acquired 4,327 common shares from RSU vesting and disposed of 1,896 shares for tax withholding on September 30, 2025.

Summary

• Andrew Cittadine, Chief Operating Officer of Monopar Therapeutics, acquired 4,327 shares of common stock on September 30, 2025, through the vesting and settlement of restricted stock units (RSUs).
• Concurrently, 1,896 shares were disposed of at a price of $81.67 per share to cover applicable withholding taxes due upon the RSU vesting.
• Following these transactions, Cittadine directly beneficially owns 48,289 shares of common stock.
• The reporting person also holds 38,674 restricted stock units, which represent a contingent right to receive one share of common stock per unit upon future vesting.
• The vested RSUs on September 30, 2025, were part of grants made on February 2, 2022 (13,000 RSUs), February 1, 2023 (15,647 RSUs), and March 4, 2025 (40,581 RSUs), each with specific quarterly vesting schedules.

Sentiment

Score: 5

Explanation: The filing details a routine insider transaction related to executive compensation (RSU vesting and tax withholding). It does not contain information that would significantly alter the company's fundamental outlook or introduce new positive or negative sentiment.

Positives

• The vesting of restricted stock units indicates continued equity compensation for a key executive, aligning management's interests with shareholders.
• The acquisition of shares through vesting demonstrates the company's commitment to its long-term incentive plans for its officers.

Negatives

• A portion of the vested shares (1,896 shares) was sold to cover tax obligations, resulting in a reduction of direct beneficial ownership from the gross vested amount.

Risks

• No new specific risks are identified in this routine insider transaction filing.

Future Outlook

The reporting person has additional restricted stock units that are scheduled to vest quarterly until December 31, 2025, for the 2022 grant; until December 31, 2026, for the 2023 grant; and until December 31, 2028, for the 2025 grant.

Industry Context

This transaction represents a routine equity compensation event for an executive, common across publicly traded companies, particularly in the biotechnology and pharmaceutical sectors, to incentivize long-term performance and align executive interests with shareholder value.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a form of executive compensation is a standard practice across various industries, including biotechnology, aligning executive incentives with company performance over time.
• The disposal of shares to cover tax obligations upon RSU vesting is also a common and expected practice, often referred to as a 'net settlement' or 'sell-to-cover' transaction, and is consistent with compensation structures at comparable companies.

Stakeholder Impact

• Shareholders: A minor, routine increase in outstanding shares due to RSU vesting, partially offset by shares withheld for taxes. This is a standard component of executive compensation and is generally anticipated.
• Employees: The transaction reflects the company's ongoing equity compensation program for its executives, which can serve as a model for broader employee incentive structures.

Next Steps

• Continued quarterly vesting of the remaining restricted stock units granted on February 2, 2022, until December 31, 2025.
• Continued quarterly vesting of the remaining restricted stock units granted on February 1, 2023, until December 31, 2026.
• Continued quarterly vesting of the remaining restricted stock units granted on March 4, 2025, until December 31, 2028.

Key Dates

Recommendation

This Form 4 details a routine vesting of restricted stock units and subsequent tax withholding for a company officer. Such transactions are standard components of executive compensation and do not typically provide new material information that would alter an investment thesis or warrant a change in recommendation. The transaction reflects pre-scheduled equity compensation rather than discretionary open market purchases or sales, thus maintaining a 'hold' recommendation based solely on this filing.

Keywords

Monopar Therapeutics, MNPR, Andrew Cittadine, COO, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Equity Compensation, Share Acquisition, Tax Withholding